News
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
The therapy is as an option for untreated intermediate or poor-risk advanced renal cell carcinoma (RCC) in adults, in circumstances when nivolumab with ipilimumab would otherwise have been offered.